Indegene’s Board of Directors has approved the unaudited standalone and consolidated financial results for Q3 2026, ending December 31, 2025. Results show revenue of ₹25,071 million on a consolidated basis. The board also approved an amendment to the Anti-Sexual Harassment Policy and allotment of shares under the RSU 2020 Plan, including a re-constitution of board committees, effective January 29, 2026.
Q3 2026 Financial Performance
The Board of Directors of Indegene Limited has approved the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Q3 2026). A limited review report from the auditors accompanied the results. Consolidated revenue reached ₹25,071 million. The standalone financial results are included. The results were formally approved on January 29, 2026.
Key Board Decisions
In addition to the financial results, the board took the following actions:
- Approved an amendment to the company’s Anti-Sexual Harassment Policy.
- Approved allotment of shares under the RSU 2020 Plan.
- Approved a re-constitution of the Committees of the Board.
Subsidiary Performance
The consolidated unaudited financial results include interim financial information from one subsidiary and six step-down subsidiaries, which haven’t been reviewed by their auditors. These subsidiaries reflect total revenue of ₹179 million for the quarter and ₹555 million for the nine months ending December 31, 2025.
Segment Restructuring
Effective October 1, 2025, the group merged the Brand Activation segment into Enterprise Commercial Solutions. Comparative period information has been recasted to reflect this change. Post-restructuring, the company reports under two segments: Enterprise Commercial Solutions and Enterprise Medical Solutions.
Audit Qualifications
The auditor’s review report indicates no material misstatements or qualifications concerning the consolidated and standalone financial results.
Source: BSE
